← Back to All US Stocks

Personalis, Inc. (PSNL) Stock Fundamental Analysis & AI Rating 2026

PSNL Nasdaq Services-Medical Laboratories DE CIK: 0001527753
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2025-12-31
SELL
85% Conf
Pending
Analysis scheduled

📊 PSNL Key Takeaways

Revenue: $69.6M
Net Margin: -116.7%
Free Cash Flow: $-79.5M
Current Ratio: 6.76x
Debt/Equity: 0.08x
EPS: $-0.91
AI Rating: SELL with 85% confidence
Personalis, Inc. (PSNL) receives a SELL rating with 85% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $69.6M, net profit margin of -116.7%, and return on equity (ROE) of -31.1%, Personalis, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete PSNL stock analysis for 2026.

Is Personalis, Inc. (PSNL) a Good Investment?

Claude

Personalis exhibits deteriorating fundamentals with declining revenue (-17.7% YoY), massive operating losses (-126.4% margin), and negative free cash flow (-$79.5M), indicating an unsustainable business model. While the company maintains a strong cash position ($124.2M) and low leverage, the burn rate and lack of profitability suggest significant distress absent a major operational turnaround.

Why Buy Personalis, Inc. Stock? PSNL Key Strengths

Claude
  • + Strong liquidity with $124.2M cash and 6.76x current ratio enabling near-term operational continuity
  • + Low leverage with 0.08x debt-to-equity ratio minimizing bankruptcy risk
  • + Solid stockholders' equity base of $261.2M providing financial cushion

PSNL Stock Risks: Personalis, Inc. Investment Risks

Claude
  • ! Revenue declining 17.7% YoY with negative free cash flow of $79.5M indicating unsustainable burn rate despite liquid reserves
  • ! Operating margin of -126.4% and net margin of -116.7% reflect fundamental business model failure with no visible path to profitability
  • ! Gross margin of only 9.4% suggests severe cost structure challenges and inability to achieve economies of scale in laboratory services

Key Metrics to Watch

Claude
  • * Revenue stabilization and return to growth or exit from decline
  • * Gross margin expansion and progress toward operating profitability
  • * Operating and free cash flow improvement to assess business sustainability

Personalis, Inc. (PSNL) Financial Metrics & Key Ratios

Revenue
$69.6M
Net Income
$-81.3M
EPS (Diluted)
$-0.91
Free Cash Flow
$-79.5M
Total Assets
$334.2M
Cash Position
$124.2M

💡 AI Analyst Insight

Strong liquidity with a 6.76x current ratio provides a solid financial cushion.

PSNL Profit Margin, ROE & Profitability Analysis

Gross Margin 9.4%
Operating Margin -126.4%
Net Margin -116.7%
ROE -31.1%
ROA -24.3%
FCF Margin -114.1%

PSNL vs Healthcare Sector: How Personalis, Inc. Compares

How Personalis, Inc. compares to Healthcare sector averages

Net Margin
PSNL -116.7%
vs
Sector Avg 12.0%
PSNL Sector
ROE
PSNL -31.1%
vs
Sector Avg 15.0%
PSNL Sector
Current Ratio
PSNL 6.8x
vs
Sector Avg 2.0x
PSNL Sector
Debt/Equity
PSNL 0.1x
vs
Sector Avg 0.6x
PSNL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Personalis, Inc. Stock Overvalued? PSNL Valuation Analysis 2026

Based on fundamental analysis, Personalis, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-31.1%
Sector avg: 15%
Net Profit Margin
-116.7%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.08x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Personalis, Inc. Balance Sheet: PSNL Debt, Cash & Liquidity

Current Ratio
6.76x
Quick Ratio
6.76x
Debt/Equity
0.08x
Debt/Assets
21.8%
Interest Coverage
-429.55x
Long-term Debt
$20.0M

PSNL Revenue & Earnings Growth: 5-Year Financial Trend

PSNL 5-year financial data: Year 2021: Revenue $85.5M, Net Income -$25.1M, EPS N/A. Year 2022: Revenue $85.5M, Net Income -$41.3M, EPS $-1.20. Year 2023: Revenue $85.5M, Net Income -$65.2M, EPS $-1.49. Year 2024: Revenue $84.6M, Net Income -$108.3M, EPS $-2.25. Year 2025: Revenue $84.6M, Net Income -$81.3M, EPS $-1.37.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Personalis, Inc.'s revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-1.37 indicates the company is currently unprofitable.

PSNL Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-114.1%
Free cash flow / Revenue

PSNL Quarterly Earnings & Performance

Quarterly financial performance data for Personalis, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $14.5M -$21.7M $-0.24
Q2 2025 $17.2M -$12.8M $-0.23
Q1 2025 $19.5M -$13.0M $-0.18
Q3 2024 $18.2M -$29.1M $-0.60
Q2 2024 $16.7M -$12.8M $-0.24
Q1 2024 $18.9M -$13.0M $-0.26
Q3 2023 $14.9M -$26.5M $-0.58
Q2 2023 $16.7M -$24.0M $-0.50

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Personalis, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$74.9M
Cash generated from operations
Capital Expenditures
$4.5M
Investment in assets
Dividends
None
No dividend program

PSNL SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Personalis, Inc. (CIK: 0001527753)

📋 Recent SEC Filings

Date Form Document Action
Apr 2, 2026 DEF 14A psnl-20260401.htm View →
Mar 17, 2026 4 xslF345X05/form4-03172026_080312.xml View →
Mar 17, 2026 4 xslF345X05/form4-03172026_080346.xml View →
Mar 17, 2026 4 xslF345X05/form4-03172026_080326.xml View →
Mar 17, 2026 4 xslF345X05/form4-03172026_080357.xml View →

Frequently Asked Questions about PSNL

What is the AI rating for PSNL?

Personalis, Inc. (PSNL) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PSNL's key strengths?

Claude: Strong liquidity with $124.2M cash and 6.76x current ratio enabling near-term operational continuity. Low leverage with 0.08x debt-to-equity ratio minimizing bankruptcy risk.

What are the risks of investing in PSNL?

Claude: Revenue declining 17.7% YoY with negative free cash flow of $79.5M indicating unsustainable burn rate despite liquid reserves. Operating margin of -126.4% and net margin of -116.7% reflect fundamental business model failure with no visible path to profitability.

What is PSNL's revenue and growth?

Personalis, Inc. reported revenue of $69.6M.

Does PSNL pay dividends?

Personalis, Inc. does not currently pay dividends.

Where can I find PSNL SEC filings?

Official SEC filings for Personalis, Inc. (CIK: 0001527753) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PSNL's EPS?

Personalis, Inc. has a diluted EPS of $-0.91.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is PSNL a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Personalis, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is PSNL stock overvalued or undervalued?

Valuation metrics for PSNL: ROE of -31.1% (sector avg: 15%), net margin of -116.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy PSNL stock in 2026?

Our dual AI analysis gives Personalis, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PSNL's free cash flow?

Personalis, Inc.'s operating cash flow is $-74.9M, with capital expenditures of $4.5M. FCF margin is -114.1%.

How does PSNL compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -116.7% (avg: 12%), ROE -31.1% (avg: 15%), current ratio 6.76 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2025-12-31 | Powered by Claude AI